Sionna Therapeutics (NASDAQ:SION) Earns Outperform Rating from Analysts at Wedbush

Equities research analysts at Wedbush began coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The brokerage set an “outperform” rating and a $53.00 price target on the stock. Wedbush’s target price suggests a potential upside of 31.03% from the stock’s current price.

Several other research firms also recently commented on SION. Raymond James Financial reissued a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday, January 5th. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. JonesTrading lifted their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Citigroup started coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set an “outperform” rating on the stock. Finally, Citizens Jmp started coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.00.

Sionna Therapeutics Stock Performance

SION stock opened at $40.45 on Tuesday. The company has a market capitalization of $1.83 billion, a PE ratio of -20.74 and a beta of 1.35. Sionna Therapeutics has a one year low of $11.77 and a one year high of $46.46. The company’s 50 day moving average price is $38.18 and its two-hundred day moving average price is $39.13.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15. On average, research analysts predict that Sionna Therapeutics will post -2.44 EPS for the current year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of Sionna Therapeutics stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,131,856 shares of company stock worth $50,834,773. 3.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Viking Global Investors LP increased its stake in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the period. Vanguard Group Inc. increased its stake in shares of Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after buying an additional 41,797 shares during the period. Jennison Associates LLC increased its stake in shares of Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after buying an additional 117,903 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Sionna Therapeutics by 30.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock worth $34,203,000 after buying an additional 193,613 shares during the period. Finally, State Street Corp increased its stake in shares of Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after buying an additional 453,196 shares during the period.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.